A Phase 1 interventional study of TAK-227 in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of this study is to test the effects of food consumption with sponsor compound TAK-227 in healthy participants. The study will also measure side effects, and to check how much TAK-227 stays in the blood over time to work out the best dose.
The drug being tested in this study is called TAK-227. This study will assess the effect of food on single-dose of TAK-227 in healthy participants.
The study will enroll approximately 24 participants. A single dose of 50 milligram (mg) TAK-227 will be administered orally under one of 3 different feeding conditions.
Participants will be randomly assigned to 1 of the 6 treatments sequences based on the 3 feeding conditions.
All participants will receive all 6 treatment regimens. This is a single-center trial. Participants will be followed up for up to 7 days after the last dose of study drug for a follow-up assessment. The overall time to participate in this study is approximately 40 days including screening period and follow-up period.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must fulfill the following inclusion criteria to be eligible for participation in the study:
Exclusion Criteria:
Participants must not be enrolled in the study if they meet any of the following criteria:
Unable to refrain from or anticipates the use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A . There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 under fasting condition as Treatment A, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B. There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 under fasting condition as Treatment A, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C. There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 1 administered with a high fat/high calorie meal 30 minutes after dosing as Treatment C, followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 2 administered with a high fat or high calorie meal 30 minutes prior to dosing as Treatment B, and further followed by TAK-227 50 mg, capsule, single oral dose on Day 1 of Treatment Period 3 under fasting condition as Treatment A. There will be a washout period of at least 4 days between each dosing.
Drug: TAK-227
TAK-227 capsules.
Cmax: Maximum Observed Plasma Concentration for TAK-227
Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227
Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227
Time frame: Day 1 pre-dose and at multiple time points (up to 36 hours) post-dose
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who had signed the informed consent form (ICF) to participate in a study; it did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence that at any dose met one or more of the following criteria: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)
Number of Participants Based on Severity of TEAE
Severity of a TEAEs were determined by following criteria: Mild: event that did not generally interfere with usual activities of daily living; Moderate: event that interfere with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupt usual activities of daily living, significantly affects clinical status, or might require intensive therapeutic intervention.
Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)
Number of Participants Based on Causality of TEAEs
Causality of TEAEs to the study medication was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that is, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.
Time frame: From start of study drug administration up to 7 days after the last dose (up to Day 20)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values
Vital signs included body temperature (oral or tympanic measurement), respiratory rate, blood pressure \[systolic blood pressure (SBP) and diastolic blood pressure (DBP)\], and pulse (beats per minute). The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.
Time frame: Baseline to Day 13
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values
ECGs was performed with participants in a supine position. All ECG tracings were reviewed by the investigator or designee. Number of participants with clinically significant change from baseline in ECG values were reported.
Time frame: Baseline to Day 13
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in laboratory values (hematology, serum chemistry, and urinalysis) were reported.
Time frame: Baseline to Day 13
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
Physical examination included the following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system (4) dermatologic system; and (5) gastrointestinal system. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in physical examination values were reported.
Time frame: Baseline to Day 13
Participants took part in the study at single investigative site in the United States from 25 May 2023 to 26 June 2023.
| Milestone | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Treatment Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Treatment Sequence 6: (Treatment C + Treatment B + Treatment A) |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Treatment Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Treatment Sequence 6: (Treatment C + Treatment B + Treatment A) |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Treatment Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Treatment Sequence 6: (Treatment C + Treatment B + Treatment A) |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Treatment Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Treatment Sequence 6: (Treatment C + Treatment B + Treatment A) |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Treatment Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Treatment Sequence 6: (Treatment C + Treatment B + Treatment A) |
|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for TAK-227 | 464.4 ± 89.8 | 190.9 ± 50.6 | 370.0 ± 102.6 |
| nanogram*hour per milliliter(ng*hr/mL) | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-227 | 1582 ± 65.9 | 969.2 ± 51.2 | 1056 ± 53.0 |
| nanogram*hour per milliliter(ng*hr/mL) | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-227 | 1708 ± 52.0 | 983.7 ± 50.8 | 1070 ± 51.8 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant who had signed the informed consent form (ICF) to participate in a study; it did not necessarily have to have a causal relationship with the treatment. An SAE was any untoward medical occurrence that at any dose met one or more of the following criteria: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event. A TEAE was defined as an adverse event with an onset that occurs after receiving study drug.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| TEAEs | 4 | 5 | 2 |
| Serious TEAEs | 0 | 0 | 0 |
Severity of a TEAEs were determined by following criteria: Mild: event that did not generally interfere with usual activities of daily living; Moderate: event that interfere with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupt usual activities of daily living, significantly affects clinical status, or might require intensive therapeutic intervention.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Mild | 3 | 5 | 2 |
| Moderate | 1 | 0 | 0 |
| Severe | 0 | 0 | 0 |
Causality of TEAEs to the study medication was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that is, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Related TEAEs | 3 | 3 | 2 |
| Not Related TEAEs | 1 | 2 | 0 |
Vital signs included body temperature (oral or tympanic measurement), respiratory rate, blood pressure \[systolic blood pressure (SBP) and diastolic blood pressure (DBP)\], and pulse (beats per minute). The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in vital signs values were reported.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values | 0 | 0 | 0 |
ECGs was performed with participants in a supine position. All ECG tracings were reviewed by the investigator or designee. Number of participants with clinically significant change from baseline in ECG values were reported.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiograms (ECG) Values | 0 | 0 | 0 |
The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in laboratory values (hematology, serum chemistry, and urinalysis) were reported.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters | 0 | 0 | 0 |
Physical examination included the following body systems: (1) respiratory system; (2) cardiovascular system; (3) nervous system (4) dermatologic system; and (5) gastrointestinal system. The clinically significant change assessment was based on investigator's judgment. Number of participants with clinically significant change from baseline in physical examination values were reported.
| Participants | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examination | 0 | 0 | 0 |
Collected over From start of study drug administration up to 7 days after the last dose (up to Day 20). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: TAK-227 50 mg | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| Treatment B: TAK-227 50 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Treatment C: TAK-227 50 mg | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Event | Treatment A: TAK-227 50 mg | Treatment B: TAK-227 50 mg | Treatment C: TAK-227 50 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 2/24 | 0/24 | 0/24 |
The safety set included all participants who received at least one dose of the study drug and were included in the safety evaluations.
| Age, Continuous(years) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 49.0 ± 6.38 | 43.0 ± 10.23 | 39.5 ± 4.20 | 42.8 ± 8.10 | 43.0 ± 7.70 | 36.5 ± 10.47 | 42.3 ± 8.19 |
| Sex: Female, Male(Participants) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 1 | 2 | 1 | 11 |
| Male | 2 | 1 | 2 | 3 | 2 | 3 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 4 | 2 | 3 | 3 | 19 |
| Not Hispanic or Latino | 0 | 1 | 0 | 2 | 1 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| White | 3 | 4 | 4 | 3 | 4 | 3 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| United States | 4 | 4 | 4 | 4 | 4 | 4 | 24 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.613 ± 2.1689 | 27.055 ± 3.4694 | 27.795 ± 4.6085 | 27.640 ± 2.7334 | 27.380 ± 3.2070 | 26.280 ± 2.0572 | 27.460 ± 2.8896 |
| Height(centimeter (cm)) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 164.5 ± 8.43 | 165.0 ± 10.03 | 162.3 ± 12.71 | 171.3 ± 11.15 | 169.8 ± 15.65 | 173.8 ± 6.65 | 167.8 ± 10.72 |
| Weight(kilogram (kg)) | Treatment Sequence 1: (Treatment A + Treatment B + Treatment C) | Sequence 2: (Treatment B + Treatment C + Treatment A) | Treatment Sequence 3: (Treatment C + Treatment A + Treatment B) | Treatment Sequence 4: (Treatment A + Treatment C + Treatment B) | Treatment Sequence 5: (Treatment B + Treatment A + Treatment C) | Sequence 6: (Treatment C + Treatment B + Treatment A) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 77.43 ± 7.135 | 74.18 ± 15.436 | 74.07 ± 18.007 | 80.78 ± 5.038 | 80.00 ± 19.588 | 79.33 ± 4.640 | 77.63 ± 11.986 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2023 to primary completion in Jun 2023, 0 months.
Results were first posted in Aug 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZED1227